Neoadjuvant Immunotherapy Clinical Trials

5 recruiting

Neoadjuvant Immunotherapy Trials at a Glance

6 actively recruiting trials for neoadjuvant immunotherapy are listed on ClinicalTrialsFinder across 6 cities. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Beijing, Guangzhou, and Hangzhou. Lead sponsors running neoadjuvant immunotherapy studies include Anhui Provincial Cancer Hospital, Peking University Cancer Hospital & Institute, and Sun Yat-sen University.

Browse neoadjuvant immunotherapy trials by phase

Treatments under study

About Neoadjuvant Immunotherapy Clinical Trials

Looking for clinical trials for Neoadjuvant Immunotherapy? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neoadjuvant Immunotherapy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neoadjuvant Immunotherapy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)

Neoadjuvant Immunotherapy
Tianjin Medical University Second Hospital21 enrolled1 locationNCT05837806
Recruiting

Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer

RadiotherapyLung Cancer (NSCLC)Neoadjuvant Immunotherapy+1 more
Peking University Cancer Hospital & Institute500 enrolled4 locationsNCT06926179
Recruiting
Phase 2

Neoadjuvant Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer

Colorectal Cancer (CRC)PD-1 InhibitorNeoadjuvant Immunotherapy+2 more
Sun Yat-sen University105 enrolled1 locationNCT06903858
Recruiting
Phase 2

Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC

NSCLCLow Dose RadiotherapyNeoadjuvant Immunotherapy+1 more
Anhui Provincial Cancer Hospital86 enrolled1 locationNCT06714708
Recruiting
Phase 2

Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer

Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer
Zhejiang Cancer Hospital20 enrolled1 locationNCT06562920
Recruiting
Phase 2

Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery

Cervical CancerNeoadjuvant ImmunotherapyFertility-sparing Surgery
Xiaohua Wu30 enrolled1 locationNCT06209294